2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 1240

A Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Anakinra in Difficult-To-Treat Acute Gouty Arthritis: The anaGO Study

Metabolic & Crystal Arthropathies Poster II: Clinical Trials & Basic Science

9:00AM-11:00AM: Abstract Number: 1498

A Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Secukinumab in US Biologic-Naive Patients with Active Psoriatic Arthritis and Psoriatic Skin Lesions

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1675

A Retrospective Cohort Study Using Clinical Notes and Latent Topic Modeling to Characterize the Natural History of ANCA-Associated Vasculitis

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 1254

A Retrospective Medical Chart Review of Patients with Periodic Fever Syndromes Initiating Canakinumab in the United States

Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies

9:00AM-11:00AM: Abstract Number: 1213

A Retrospective Review and Prospective Intervention for Outpatient Follow-Up of Hospitalized Patients in Rheumatology

Measures Of Healthcare Quality Poster II: Improving Care

9:00AM-11:00AM: Abstract Number: 1751

A Systematic Literature Review of Efficacy and Safety of Biologic Agents for the Treatment of Juvenile Dermatomyositis

Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

9:00AM-11:00AM: Abstract Number: 1065

Aberrant Expression Levels of Soluble Co-inhibitory Receptors Linked to Disease Activity in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1292

Abnormal High Density Lipoprotein Particle Size and Number in Idiopathic Inflammatory Myopathies

Muscle Biology, Myositis & Myopathies Poster II

9:00AM-11:00AM: Abstract Number: 1516

Achievement of RAPID3 and cDAPSA Treatment Targets Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psoriatic Arthritis in Subjects Treated with Apremilast

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1347

Achievement of Remission in Two Early Rheumatoid Arthritis Cohorts Implementing Different Treat-To-Target Strategies

RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

9:00AM-11:00AM: Abstract Number: 1535

Achievement of Very Low Disease Activity and Remission Treatment Targets Is Associated with Reduced Radiographic Progression in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1435

Acute Effects of IL-6 Blockade, TNFα Inhibitor or Glucocorticoids on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1679

Adaptive Study Design of a Randomized, Multicenter, 2-Part Phase 2 Trial of Replacement of Glucocorticoids by IFX-1, a C5a Inhibitor, in Active Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 1372

Adherence to Treatment with Intravenous Biological Agents in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures – ARP

9:00AM-11:00AM: Abstract Number: 981

Adipocytokines and Obesity in the Context of Rheumatoid and Osteoarthritis Mouse Models

RA – Animal Models Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].